Bioventus Looks to Regain Credibility With Investors
The company's 1Q23 orthopedic sales declined slightly as Bioventus embarks upon a quarters-long turnaround....
The company's 1Q23 orthopedic sales declined slightly as Bioventus embarks upon a quarters-long turnaround....
The company grew its orthopedic business 9% in 1Q23, driven by favorable order timing and contributions from new products....
The company grew over 45% in 1Q23 as it further penetrates the large, underserved bunion surgical procedure market....
The company grew 26% in 1Q23 against strong comps than most of the orthopedic industry, but opted to not increase...
The company grew 11.1% on a pro forma basis in 1Q23, driven by strength across its businesses and no major...
The company grew more than 30% in the first quarter of 2023 despite ongoing staffing challenges at pediatric hospitals....
The company grew 20% in 1Q23 due to improving procedure volumes, competitive rep recruiting and robotic pull-through....
The company's 1Q23 sales declined in the high teens as its business model shift and operational challenges take a toll....
The company grew in the high teens in 1Q23 due to easing market pressures in the U.S. and some international...
The company grew 54% in 1Q23 and acquired the REMI navigated robotics system as ATEC prepares for the modernization of...
Login
Register for a free account
As a guest member you get access to more articles and webinars every month.